Issue Date: March 5, 2007
IN A BID TO LOWER health care costs for consumers and insurers, Congress is pushing legislation to expand and speed up the availability of generic drugs, including less expensive versions of boutique biotechnology-based medicines used to treat heart disease and other serious conditions.
Bills introduced in the House and Senate on Feb. 14 would empower the Food & Drug Administration to approve generic counterparts to biotech drugs without requiring the generics manufacturers to repeat . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society